EP2035004B1 - Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity - Google Patents

Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity Download PDF

Info

Publication number
EP2035004B1
EP2035004B1 EP07784388A EP07784388A EP2035004B1 EP 2035004 B1 EP2035004 B1 EP 2035004B1 EP 07784388 A EP07784388 A EP 07784388A EP 07784388 A EP07784388 A EP 07784388A EP 2035004 B1 EP2035004 B1 EP 2035004B1
Authority
EP
European Patent Office
Prior art keywords
chor
independently
alkyl
phenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07784388A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2035004A1 (en
EP2035004A4 (en
Inventor
Michael Ross Johnson
Andrew J. HIRCH
Richard C. Boucher
Jianzhong Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parion Sciences Inc
Original Assignee
Parion Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parion Sciences Inc filed Critical Parion Sciences Inc
Priority to SI200731054T priority Critical patent/SI2035004T1/sl
Priority to PL07784388T priority patent/PL2035004T3/pl
Publication of EP2035004A1 publication Critical patent/EP2035004A1/en
Publication of EP2035004A4 publication Critical patent/EP2035004A4/en
Application granted granted Critical
Publication of EP2035004B1 publication Critical patent/EP2035004B1/en
Priority to CY20121101054T priority patent/CY1113369T1/el
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C07D241/32—(Amino-pyrazinoyl) guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to sodium channel blockers possessing beta-adrenergic receptor agonist activity.
  • the present invention also includes a variety of uses with these sodium channel blockers/ beta-adrenergic receptor agonists.
  • the mucosal surfaces at the interface between the environment and the body have evolved a number of "innate defenses", i.e., protective mechanisms.
  • a principal form of such an innate defense is to cleanse these surfaces with liquid.
  • the quantity of the liquid layer on a mucosal surface reflects the balance between epithelial liquid secretion, often reflecting anion (Cl - and/or HCO 3 - ) secretion coupled with water (and a cation counter-ion), and epithelial liquid absorption, often reflecting Na + absorption, coupled with water and counter anion (Cl - and/or HCO 3 - ).
  • One approach to replenish the protective liquid layer on mucosal surfaces is to "re-balance" the system by blocking Na + channel and liquid absorption and simultaneously activating beta-adrenergic receptors thereby causing liquid secretion.
  • the epithelial protein that mediates the rate-limiting step of Na + and liquid absorption is the epithelial Na + channel (ENaC).
  • ENaC and beta-adrenergic receptors are positioned on the apical surface of the epithelium, i.e. the mucosal surface-extermal environment interface.
  • an ENaC blocker of the amiloride class (which blocks from the extracellular domain of ENaC) must be delivered to the mucosal surface and, importantly, be maintained at this site, to achieve therapeutic utility.
  • the present invention describes diseases characterized by too little liquid on mucosal surfaces and "topical" sodium channel blockers containing beta-adrenergic receptor agonist activity designed to exhibit the increased potency, reduced mucosal abosrption, and slow dissociation ("unbinding" or detachment) from ENaC and the beta-adrenergic receptor required for therapy of these diseases.
  • Chronic bronchitis including the most common lethal genetic form of chronic bronchitis, cystic fibrosis (CF), are diseases that reflect the body's failure to clear mucus normally from the lungs, which ultimately produces chronic airways infection.
  • CB chronic bronchitis
  • CF cystic fibrosis
  • chronic bronchitis the primary defense against chronic intrapulmonary airways infection
  • This function in health subjects effectively removes from the lung potentially noxious toxins and pathogens.
  • Recent data indicate that the initiating problem, i.e., the "basic defect," in both CB and CF is the failure to clear mucus from airway surfaces.
  • ASL airway surface liquid
  • PCL peripheral liquid
  • This imbalance results in a relative reduction in ASL which leads to mucus concentration, a reduction in the lubricant activity of the PCL, and a failure to clear mucus via ciliary activity to the mouth.
  • the reduction in mechanical clearance of mucus from the lung leads to chronic bacterial colonization of mucus adherent to airway surfaces. It is the chronic retention of bacteria, the failure of local antimicrobial substances to kill mucus-entrapped bacteria on a chronic basis, and the consequent chronic inflammatory responses of the body to this type of surface infection, that lead to the syndromes of CB and CF.
  • the current afflicted population in the U.S. is 12,000,000 patients with the acquired (primarily from cigarette smoke exposure) form of chronic bronchitis and approximately 30,000 patients with the genetic form, cystic fibrosis. Approximately equal numbers of both populations are present in Europe. In Asia, there is little CF but the incidence of CB is high and, like the rest of the world, is increasing.
  • a major unmet therapeutic need for both CB and CF lung diseases is an effective means of re-hydrating airway mucus (i.e., restoring/expanding the volume of the ASL) and promoting its clearance, with bacteria, from the lung.
  • R.C. Boucher in U.S. 6,264,975 , describes the use of pyrazinoylguanidine sodium channel blockers for hydrating mucosal surfaces.
  • These compounds typified by the well-known diuretics amiloride, benzamil, and phenamil, are effective.
  • these compounds suffer from the significant disadvantage that they are (1) relatively impotent, which is important because the mass of drug that can be inhaled by the lung is limited; (2) rapidly absorbed, which limits the half-life of the drug on the mucosal surface; and (3) are freely dissociable from ENaC.
  • the sum of these disadvantages embodied in these well known diurectics produces compounds with insufficient potency and/or effective half-life on mucosal surfaces to have therapeutic benefit for hydrating mucosal surfaces.
  • mucosal surfaces in and on the body exhibit subtle differences in the normal physiology of the protective surface liquids on their surfaces but the pathophysiology of disease reflects a common theme, i.e., too little protective surface liquid.
  • xerostomia dry mouth
  • the oral cavity is depleted of liquid due to a failure of the parotid sublingual and submandibular glands to secrete liquid despite continued Na + (ENaC) transport mediated liquid absorption from the oral cavity.
  • keratoconjunctivitis sira dry eye is caused by failure of lacrimal glands to secrete liquid in the face of continued Na + dependent liquid absorption on conjunctional surfaces.
  • WO 2005 018644 discloses compounds similar to the present ones for treating the present disorders.
  • the present disclosure describes methods of treatment that take advantage of the pharmacological properties of the compounds described above.
  • the present disclosure describes methods of treatment which rely on rehydration of mucosal surfaces.
  • any of the compounds described herein can be a pharmaceutically acceptable salt thereof, and wherein the above compounds are inclusive of all racemates, enantiomers, diastereomers, tautomers, polymorphs and pseudopolymorphs thereof.
  • Polymorphs are different physical forms - different crystal forms that have differing melting ranges, show differing differential scanning calorimetry (DSC) tracings and exhibit different X-Ray powder diffraction (XRPD) spectra.
  • Pseudopolymorphs are different solvated physical forms - different crystal forms that have differing melting ranges as solvates, show differing differential scanning calorimetry (DSC) tracings as solvates and exhibit different X-Ray powder diffraction (XRPD) spectra as solvates.
  • DSC differential scanning calorimetry
  • XRPD X-Ray powder diffraction
  • the present invention also provides pharmaceutical compositions which contain a compound described above.
  • the present disclosure also describes a method of promoting hydration of mucosal surfaces, comprising:
  • the present disclosure also describes a method of restoring mucosal defense, comprising:
  • the present disclosure also describes a method of blocking ENaC and exerting beta-adrenergic receptor agonism comprising:
  • the present disclosure also describes a method of promoting mucus clearance in mucosal surfaces, comprising:
  • the present disclosure also describes a method of treating chronic bronchitis, comprising:
  • the present disclosure also describes a method of treating cystic fibrosis, comprising:
  • the present disclosure also describes a method of treating rhinosinusitis, comprising:
  • the present disclosure also describes a method of treating nasal dehydration, comprising:
  • nasal dehydration is brought on by administering dry oxygen to the subject.
  • the present disclosure also describes a method of treating sinusitis, comprising:
  • the present disclosure also describes a method of treating pneumonia, comprising:
  • the present disclosure also describes a method of preventing ventilator-induced pneumonia, comprising:
  • the present disclosure also describes a method of treating asthma, comprising:
  • the present disclosure also describes a method of treating primary ciliary dyskinesia, comprising:
  • the present disclosure also describes a method of treating otitis media, comprising:
  • the present disclosure also describes a method of inducing sputum for diagnostic purposes, comprising:
  • the present disclosure also describes a method of treating chronic obstructive pulmonary disease, comprising:
  • the present disclosure also describes a method of treating emphysema, comprising:
  • the present disclosure also describes a method of treating dry eye, comprising:
  • the present disclosure also describes a method of promoting ocular hydration, comprising:
  • the present disclosure also describes a method of promoting corneal hydration, comprising:
  • the present disclosure also describes a method of treating Sjögren's disease, comprising:
  • the present disclosure also describes a method of treating vaginal dryness, comprising:
  • the present disclosure also describes a method of treating dry skin, comprising:
  • the present disclosure also describes a method of treating dry mouth (xerostomia), comprising:
  • the present disclosure also describes a method of treating distal intestinal obstruction syndrome, comprising:
  • the present disclosure also describes a method of treating esophagitis, comprising:
  • the present disclosure also describes a method of treating constipation, comprising:
  • the compound is administered either orally or via a suppository or enema.
  • the present disclosure also describes a method of treating chronic diverticulitis comprising:
  • the present invention also provides the use of an effective amount of a compound represented by formula (I) in the manufacture of a medicament for treating one or more conditions selected from the group consisting of chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, chronic diverticulitis, and rhinosinusitis.
  • chronic bronchitis chronic bronchitis
  • cystic fibrosis cystic fibrosis
  • sinusitis vaginal dryness
  • dry eye dry eye
  • Sjogren's disease distal intestinal obstruction syndrome
  • dry skin esophagitis
  • dry mouth xerostomia
  • nasal dehydration ventilator-induced pneumonia
  • the present invention also provides a compound represented by formula (I) for use as a medicament.
  • the present invention is based on the discovery that the compounds of formula (I) also possess both sodium channel blocking activity and beta agonist activity in the same molecule.
  • the present invention is also based on the discovery that the compounds of formula (I) are more potent and/or, absorbed less rapidly from mucosal surfaces, especially airway surfaces, and/or less reversible from interactions with ENaC as compared to compounds such as amiloride, benzamil, and phenamil. Therefore, the compounds of formula (I) have a longer half-life on mucosal surfaces as compared to these compounds.
  • the present invention is also based on the discovery that certain compounds embraced by formula (I) are converted in vivo into metabolic derivatives thereof that have reduced efficacy in blocking sodium channels and acting as beta-adrenergic receptor agonists as compared to the parent administered compound, after they are absorbed from mucosal surfaces after administration.
  • This important property means that the compounds will have a lower tendency to cause undesired side-effects by blocking sodium channels and activating beta-receptors located at other untargeted locations in the body of the recipient, e.g., in the kidneys and heart..
  • a single molecular entity which can simultaneously modulate multiple drug targets (designed multiple ligands).
  • the advantage of a multiple ligand over the first two approaches is that it improves compliance, enhances efficacy, it targets a known set of deficiencies in multiple systems with a single new chemical entity, it often lacks the unpredictable differences in the pharmacokinetic and pharmacodynamic variability between patients, it is often easier to formulate and potentially lowers the risk of drug-drug interactions compared to drug cocktails and multiple component drugs. It was therefore our goal to discover multiple ligands that have both sodium channel blocking activity as well as beta agonist activity.
  • beta-adrenergic receptor agonist activity to a sodium channel blocker will significantly increase the capacity to hydrate airway surfaces in subjects in need of hydration for therapeutic purposes.
  • Na + channel blocker inhibits the entry of Na + into the cell which: (1) abolishes Na + absorption and (2) hyperpolarizes the apical cell membrane(Va).
  • the hyperpolarization of Va generates an electrochemical driving force favoring Cl - secretion (Na + now follows in the secretory direction via the paracellular path).
  • the rate of Cl - secretion is proportional to the activity of the apical membrane Cl - channels which are typically 30-50% maximally active under basal conditions.
  • application of a Na + channel blocker inhibits Na + absorption and triggers a modest amount of Cl - secretion. Note again that water will follow transcellularly in response to the secreted NaCl.
  • the compounds of formula I exist primarily as a combination of the three tautomers shown in Figure 4.
  • Figure 4 shows the three tautomers represented in formula I that exist in solution.
  • Previous studies by Smith et al. have shown that the free base exists primarily as the acylimino tautomer, whereas the physiologically active species exists as the protonated form of the acylamino tautomer ( Figure 1 , refRL Smith et. Al. Journal of the American Chemical Society, 1979, 101, 191-201 ).
  • Figure 1 refRL Smith et. Al. Journal of the American Chemical Society, 1979, 101, 191-201
  • These structural representations have been used to represent amiloride and its analogs in both the patent and scientific literature.
  • We use both the acylamino and acylimino representations for convenience throughout this patent with the understanding that the structures are in reality a hybrid of the three forms with the actual amount of each dependent on the pH, the cite of action and the nature of the substituents.
  • X may be hydrogen, halogen, trifluoromethyl, C 1 -C 7 alkyl, C 1 -C 7 cycloalkyl, unsubstituted or substituted phenyl, C 1 -C 7 alkyl-thio, phenyl-C 1 -C 7 alkyl-thio, C 1 -C 7 alkyl-sulfonyl, or phenyl- C 1 -C 7 alkyl-sulfonyl.
  • Halogen is preferred.
  • halogen examples include fluorine, chlorine, bromine, and iodine. Chlorine and bromine are the preferred halogens. Chlorine is particularly preferred. This description is applicable to the term "halogen" as used throughout the present disclosure.
  • lower alkyl means an alkyl group having less than 8 carbon atoms. This range includes all specific values of carbon atoms and subranges there between, such as 1 ,2, 3, 4, 5, 6, and 7 carbon atoms.
  • alkyl embraces all types of such groups, e.g., linear, branched, and cyclic alkyl groups. This description is applicable to the term “lower alkyl” as used throughout the present disclosure. Examples of suitable lower alkyl groups include methyl, ethyl, propyl, cyclopropyl, butyl, isobutyl, etc.
  • Substituents for the phenyl group include halogens. Particularly preferred halogen substituents are chlorine and bromine.
  • Y may be hydrogen, hydroxyl, mercapto, C 1 -C 7 alkoxy, C 1 -C 7 alkyl-thio, halogen, C 1 -C 7 alkyl, C 1 -C 7 cycloalkyl, phenyl group , or -N(R 2 ) 2 .
  • the alkyl moiety of the lower alkoxy groups is the same as described above.
  • Examples of mononuclear aryl include phenyl groups.
  • the phenyl group may be unsubstituted or substituted as described above.
  • the preferred identity of Y is -N(R 2 ) 2 . Particularly preferred are such compounds where each R 2 is hydrogen.
  • R 1 may be hydrogen or C 1 -C 7 alkyl. Hydrogen is preferred for R 1 .
  • Hydrogen and C 1 -C 7 alkyl, particularly C 1 -C 3 alkyl are preferred for R 2 . Hydrogen is particularly preferred.
  • R 3 and R 4 may be, independently, hydrogen, a group represented by formula (A), C 1 -C 7 alkyl, hydroxy C 1 -C 7 alkyl, phenyl, phenyl-C 1 -C 7 alkyl, (halophenyl)-C 1 -C 7 alkyl, C 1 -C 7 (alkylphenylalkyl), C 1 -C 7 (alkoxyphenyl)-C 1 -C 7 alkyl, naphthyl-C 1 -C 7 alkyl, or pyridyl-C 1 -C 7 alkyl, provided that at least one of R 3 and R 4 is a group represented by formula (A).
  • Preferred compounds are those where one of R 3 and R 4 is hydrogen and the other is represented by formula (A).
  • the moiety -(C(R L ) 2 ) o -X-(C(R L ) 2 ) p - defines an alkylene group bonded to the aromatic ring.
  • the variables o and p may each be an integer from 0 to 10, subject to the proviso that the sum of o and p in the chain is from 1 to 10.
  • o and p may each be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • the sum of o and p can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or any subrange therebetween.
  • the sum of o and p is from 2 to 6. In a particularly preferred embodiment, the sum of o and p is 4.
  • Each R L may be, independently, -R 7 , -(CH 2 ) n -OR 8 , -O-(CH 2 ) m -OR 8 , -(CH 2 ) n -NR 7 R 10 , -O-(CH 2 ) m -NR 7 R 10 , -(CH 2 ) n (CHOR 8 )(CHOR 8 ) n -CH 2 OR 8 , -O-(CH 2 ) m (CHOR 8 )(CHOR 8 ) n -CH 2 OR 8 , - (CH 2 CH 2 O) m -R 8 , -O-(CH 2 CH 2 O) m -R 8 , -(CH 2 CH 2 O) m -CH 2 CH 2 NR 7 R 10 , -O-(CH 2 CH 2 O) m -CH 2 CH 2 NR 7 R 10 , -O-(CH 2 CH 2 O) m -CH 2 CH 2 NR 7
  • the preferred R L groups include -H, -OH, -N(R 7 ) 2 , especially where each R 7 is hydrogen.
  • the alkylene chain in formula (A) it is preferred that when one R L group bonded to a carbon atoms is other than hydrogen, then the other R L bonded to that carbon atom is hydrogen, i.e., the formula -CHR L -. It is also preferred that at most two R L groups in an alkylene chain are other than hydrogen, where in the other R L groups in the chain are hydrogens. Even more preferably, only one R L group in an alkylene chain is other than hydrogen, where in the other R L groups in the chain are hydrogens. In these embodiments, it is preferable that x represents a single bond.
  • all of the R L groups in the alkylene chain are hydrogen.
  • the alkylene chain is represented by the formula - (CH 2 ) o -x-(CH 2 ) p -.
  • each R 5 is, independently,
  • Link -(CH 2 ) n -CR 11 R 11 -CAP Link -(CH 2 ) n (CHOR 8 )(CHOR 8 ) n -CR 11 R 11 -CAP, Link -(CH 2 CH 2 O) m -CH 2 -CR 11 R 11 -CAP, Link -(CH 2 CH 2 O) m -CH 2 CH 2 -CR 11 R 11 -CAP, Link - (CH 2 ) n -(Z) g -CR 11 R 11 -CAP, Link - (CH 2 ) n (Z) g -(CH 2 ) m -CR 11 R 11 -CAP, Link -(CH 2 ) n -NR 13 -CH 2 (CHOR 8 )(CHOR 8 ) n -CR 11 R 11 -CAP, Link-(CH 2 ) n -(CHOR 8 ) m CH 2 -NR 13 -(Z) g -CR 11 R 11 -CAP, Link-
  • Each CAP is, independently,
  • Each R 6 is, independently, -R 7 , -OR 7 -OR 11 , -N(R 7 ) 2 , -(CH 2 ) m -OR 8 , -O-(CH 2 ) m -OR 8 , -(CH 2 ) n -NR 7 R 10 , -O-(CH 2 ) m -NR 7 R 10 , -(CH 2 ) n (CHOR 8 )(CHOR 8 ) n -CH 2 OR 8 , -O-(CH 2 ) m (CHOR 8 )(CHOR 8 ) n -CH 2 OR 8 , -(CH 2 CH 2 O) m -R 8 , -O-(CH 2 CH 2 O) m -R 8 , -(CH 2 CH 2 O) m -CH 2 CH 2 NR 7 R 10 , -O-(CH 2 CH 2 O) m -CH 2 CH 2 NR 7 R 10 , -
  • Each R 7 is, independently, hydrogen C 1 -C 7 alkyl, phenyl, or substituted phenyl.
  • Each R 11 is, independently, hydrogen, C 1 -C 7 alkyl, phenyl C 1 -C 7 alkyl or substituted phenyl C 1 -C 7 alkyl.
  • Each Het is independently, -NR 13 , -S-, -SO-, -SO 2 -, -O-, -SO 2 NR 13 -, -NHSO 2 -,-NR 13 CO-, or -CONR 13 -.
  • Each g is, independently, an integer from 1 to 6.
  • Each m is, independently, an integer from 1 to 7.
  • n is, independently, an integer from 0 to 7.
  • Each Q is, independently, C-R 5 , C-R 6 , or a nitrogen atom, wherein at least one Q is C-R 5 , and where at most three Q in a ring are nitrogen atoms;
  • Each V is, independently, -(CH 2 ) m -NR 7 R 10 , -(CH 2 ) m -NR 7 R 7 , -(CH 2 ) m - + NR 11 R 11 R 11 , -(CH 2 ) n -(CHOR 8 ) m -(CH 2 ) m -(CH 2 ) m NR 7 R 10 , -(CH 2 ) n -NR 10 R 10 + -(CH 2 ) n -(CHOR 8 ) m -(CH 2 ) m NR 7 R 7 ,-(CH 2 ) n -(CHOR 8 ) m -(CH 2 ) m NR 11 R 11 R 11 with the proviso that when V is attached directly to a nitrogen atom, then V can also be, independently, R 7 , R 10 , or (R 11 ) 2 ;
  • the R 8 groups when two -CH 2 OR 8 groups are located 1,2- or 1,3- with respect to each other the R 8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
  • the alkyl moieties of the two R 6 may be bonded together to form a methylenedioxy group.
  • the R 8 groups when at least two -CH 2 OR 8 are located adjacent to each other, the R 8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.
  • one of more of the R 6 groups can be one of the R 5 groups which fall within the broad definition of R 6 set forth above.
  • the alkyl moieties of the two R 6 groups may be bonded together to form a methylenedioxy group, i.e., a group of the formula -O-CH 2 -O-.
  • R 6 may be hydrogen. Therefore, 1, 2, 3, or 4 R 6 groups may be other than hydrogen. Preferably at most 3 of the R 6 groups are other than hydrogen.
  • each g is, independently, an integer from 1 to 6. Therefore, each g may be 1, 2, 3, 4, 5, or 6.
  • each m is an integer from 1 to 7. Therefore, each m may be 1, 2, 3, 4, 5, 6, or 7.
  • Each n is an integer from 0 to 7. Therefore, each n may be 0, 1, 2, 3, 4, 5, 6, or 7.
  • Each Q in formula (A) is C-R 5 , C-R 6 , or a nitrogen atom, in which at least one Q is C-R 5 where at most three Q in a ring are nitrogen atoms.
  • at most two Q are nitrogen atoms.
  • at most one Q is a nitrogen atom.
  • the nitrogen atom is at the 3-position of the ring.
  • each Q is either C-R 5 or C-R 6 , i.e., there are no nitrogen atoms in the ring.
  • one Q is C-R 5 .
  • Y is -NH 2 .
  • R 2 is hydrogen
  • R 1 is hydrogen
  • X is chlorine
  • R 3 is hydrogen
  • R L is hydrogen
  • o is 4.
  • p is 0.
  • the sum of o and p is 4.
  • x represents a single bond.
  • R 6 is hydrogen
  • At most one Q is a nitrogen atom.
  • no Q is a nitrogen atom.
  • the compound of formula (1) is represented by the formula: In another preferred embodiment of the present invention the compound of formula (1) is represented by the formula:
  • the compound of formula (1) is represented by the formula: In another preferred embodiment of the present invention the compound of formula (1) is represented by the formula:
  • the compound of formula (1) is represented by the formula: In another preferred embodiment of the present invention the compound of formula (1) is represented by the formula:
  • the compound of formula (1) is represented by the formula: In another preferred embodiment of the present invention the compound of formula (1) is represented bv the formula:
  • the compounds of formula (I) may be prepared and used as the free base. Alternatively, the compounds may be prepared and used as a pharmaceutically acceptable salt.
  • Pharmaceutically acceptable salts are salts that retain or enhance the desired biological activity of the parent compound and do not impart undesired toxicological effects.
  • salts are (a) acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (b) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, malonic acid, sulfosalicylic acid, glycolic acid, 2-hydroxy-3-naphthoate, pamoate, salicylic acid, stearic acid, phthalic acid, mandelic acid,
  • the compounds of formula (1) function in vivo as sodium channel blockers and as beta receptor agonists.
  • the compounds of formula (I) reduce the absorption of water by the mucosal surfaces. This effect increases the volume of protective liquids on mucosal surfaces, rebalances the system, and thus treats disease.
  • the present invention also provides a compound represented by formula (I) for use as a medicament
  • Another aspect of the present invention is the use of an effective amount of a compound represented by formula (I) in the manufacture of a medicament for treating one or more conditions selected from the group consisting of chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, chronic diverticulitis, and rhinosinusitis.
  • subjects that may be treated by compounds of the present invention include, patients afflicted with cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive airway disease, artificially ventilated patients, patients with acute pneumonia.
  • the present compounds may be used to obtain a sputum sample from a patient by administering the active compounds to at least one lung of a patient, and then inducing or collecting a sputum sample from that patient.
  • the compounds will be administered to respiratory mucosal surfaces via aerosol (liquid or dry powders) or lavage.
  • Subjects that may be treated by the method described in the present disclosure also include patients being administered supplemental oxygen nasally (a regimen that tends to dry the airway surfaces); patients afflicted with an allergic disease or response (e.g., an allergic response to pollen, dust, animal hair or particles, insects or insect particles, etc.) that affects nasal airway surfaces; patients afflicted with a bacterial infection e.g., staphylococcus infections such as Staphylococcus aureus infections, Hemophilus influenza infections, Streptococcus pneumoniae infections, Pseudomonas aeuriginosa infections, etc.) of the nasal airway surfaces; patients afflicted with an inflammatory disease that affects nasal airway surfaces; or patients afflicted with sinusitis (wherein the active agent or agents are administered to promote drainage of congested mucous secretions in the sinuses by administering an amount effective to promote drainage of congested fluid in the sinuses), or combined, Rhinosinusitis.
  • the invention may
  • the present invention may be used to hydrate mucosal surfaces other than airway surfaces.
  • mucosal surfaces include gastrointestinal surfaces, oral surfaces, genito-urethral (vaginal) surfaces, ocular surfaces or surfaces of the eye, the inner ear and the middle ear.
  • the active compounds of the present invention may be administered by any suitable means, including locally/topically, orally, or rectally, in an effective amount.
  • the present invention also concerns the use of an effective amount of a compound represented by formula (I) in the manufacture of a medicament for the treatment of one or more conditions selected from the group consisting of chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, chronic diverticulitis, and rhinosinusitis; wherein said treatment comprises administering an effective amount of a compound represented by formula (I) to a subject in need thereof.
  • the present invention is concerned primarily with the treatment of human subjects, but may also be employed for the treatment of other mammalian subjects, such as dogs and cats, for veterinary purposes.
  • the compounds used to prepare the compositions of the present invention may be in the form of a pharmaceutically acceptable free base. Because the free base of the compound is generally less soluble in aqueous solutions than the salt, free base compositions are employed to provide more sustained release of active agent to the lungs. An active agent present in the lungs in particulate form which has not dissolved into solution yet serves as a depot of drug which gradually becomes bioavailable as it slowly dissolves into solution.
  • compositions comprising a compound of formula (I) in a pharmaceutically acceptable carrier (e.g., an aqueous carrier solution).
  • a pharmaceutically acceptable carrier e.g., an aqueous carrier solution.
  • the compound of formula (I) is included in the composition in an amount effective to inhibit the reabsorption of water by mucosal surfaces.
  • the compounds of the present invention may also be used in conjunction with a P2Y2 receptor agonist or a pharmaceutically acceptable salt thereof (also sometimes referred to as an "active agent” herein).
  • the composition may further comprise a P2Y2 receptor agonist or a pharmaceutically acceptable salt thereof (also sometimes referred to as an "active agent” herein).
  • the P2Y2 receptor agonist is typically included in an amount effective to stimulate chloride and water secretion by airway surfaces, particularly nasal airway surfaces. Suitable P2Y2 receptor agonists are described in columns 9-10 of U.S. 6,264,975 , U.S. 5,656,256 , and U.S. 5,292,498
  • Bronchodilators can also be used in combination with compounds of the present invention. These bronchodilators include, but are not limited to, anticholinergic agents including but not limited to ipratropium bromide, as well as compounds such as theophylline and aminophylline. These compounds may be administered in accordance with known techniques, either prior to or concurrently with the active compounds described herein.
  • Ionic and organic osmolytes can also be used in combination with compounds of the present invention.
  • Ionic osmolytes useful include any salt consisting of a pharmaceutically acceptable anion and a pharmaceutical cation.
  • Organic osmolytes include, but are not limited to, sugars, sugar alcohols and organic osmolytes. Detailed examples of ionic and non-ionic osmolytes are given in US Patent 6,926,911 .
  • a particularly useful ionic osmolyte is hypertonic sodium chloride or sodium nitrite.
  • a particularly useful organic osmolyte is the reduced sugar mannitol.
  • Another aspect of the present invention is a pharmaceutical formulation, comprising an active compound as described above in a pharmaceutically acceptable carrier (e.g., an aqueous carrier solution).
  • a pharmaceutically acceptable carrier e.g., an aqueous carrier solution.
  • the active compound is included in the composition in an amount effective to treat mucosal surfaces, such as inhibiting the reabsorption of water by mucosal surfaces, including airway and other surfaces.
  • the active compounds disclosed herein may be administered to mucosal surfaces by any suitable means, including topically, orally, rectally, vaginally, ocularly and dermally, etc.
  • the active compounds may be administered orally or rectally to the gastrointestinal mucosal surface.
  • the active compound may be combined with a pharmaceutically acceptable carrier in any suitable form, such as sterile physiological or dilute saline or topical solution, as a droplet, tablet or the like for oral administration, as a suppository for rectal or genito-urethral administration, etc.
  • Excipients may be included in the formulation to enhance the solubility of the active compounds, as desired.
  • the active compounds disclosed herein may be administered to the airway surfaces of a patient by any suitable means, including as a spray, mist, or droplets of the active compounds in a pharmaceutically acceptable carrier such as physiological or dilute saline solutions or distilled water.
  • a pharmaceutically acceptable carrier such as physiological or dilute saline solutions or distilled water.
  • the active compounds may be prepared as formulations and administered as described in U.S. Patent No. 5,789,391 to Jacobus.
  • Solid or liquid particulate active agents prepared for practicing the present invention could, as noted above, include particles ofrespirable or non-respirable size; that is, for respirable particles, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs, and for non-respirable particles, particles sufficiently large to be retained in the nasal airway passages rather than pass through the larynx and into the bronchi and alveoli of the lungs.
  • particles ranging from about I to 5 microns in size (more particularly, less than about 4.7 microns in size) are respirable.
  • Particles of non-respirable size are greater than about 5 microns in size, up to the size of visible droplets.
  • a particle size in the range of 10-500 ⁇ m may be used to ensure retention in the nasal cavity.
  • active agents or the physiologically acceptable salts or free bases thereof are typically admixed with, inter alia, an acceptable carrier.
  • the carrier must be compatible with any other ingredients in the formulation and must not be deleterious to the patient.
  • the carrier must be solid or liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a capsule, that may contain 0.5% to 99% by weight of the active compound.
  • One or more active compounds may be incorporated in the formulations of the invention, which formulations may be prepared by any of the well-known techniques of pharmacy consisting essentially of admixing the components.
  • compositions containing respirable or non-respirable dry particles of micronized active agent may be prepared by grinding the dry active agent with a mortar and pestle, and then passing the micronized composition through a 400 mesh screen to break up or separate out large agglomerates.
  • the particulate active agent composition may optionally contain a dispersant which serves to facilitate the formulation of an aerosol.
  • a suitable dispersant is lactose, which may be blended with the active agent in any suitable ratio (e.g., a 1 to 1 ratio by weight).
  • Active compounds disclosed herein may be administered to airway surfaces including the nasal passages, sinuses and lungs of a subject by a suitable means know in the art, such as by nose drops, mists, etc.
  • the active compounds of the present invention and administered by transbronchoscopic lavage are deposited on lung airway surfaces by administering an aerosol suspension of respirable particles comprised of the active compound, which the subject inhales.
  • the respirable particles may be liquid or solid. Numerous inhalers for administering aerosol particles to the lungs of a subject are known.
  • Inhalers such as those developed by Nolctar Therapeutic Systems, Palo Alto, California, USA, may be employed, including but not limited to those disclosed in U.S. Patent Nos. 5,740,794 ; 5,654,007 ; 5,458,135 ; 5,775,320 ; and 5,785,049
  • the Applicant specifically intends that the disclosures of all patent references cited herein be incorporated by reference herein in their entirety.
  • Inhalers such as those developed by Dura Pharmaceuticals, Inc., San Diego, California, USA, may also be employed, including those disclosed in U.S. Patent Nos.
  • inhalers such as those developed by Aradigm Corp., Hayward, California, USA, may be employed, including but not limited to those disclosed in U.S. Patent Nos. 5,826,570 ; 5,813,397 ; 5,819,726 ; and 5,655,516 , These apparatuses are particularly suitable as dry particle inhalers.
  • Aerosols of liquid particles comprising the active compound may be produced by any suitable means, such as with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer. See, e.g., U.S. Patent No. 4,501,729 , Nebulizers are commercially available devices which transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of compressed gas, typically air or oxygen, through a narrow venturi orifice or by means of ultrasonic agitation. Suitable formulations for use in nebulizers consist of the active ingredient in a liquid carrier, the active ingredient comprising up to 40% w/w of the formulation, but preferably less than 20% w/w.
  • the carrier is typically water (and most preferably sterile, pyrogen-free water) or dilute aqueous alcoholic solution. Perfluorocarbon carriers may also be used.
  • Optional additives include preservatives if the formulation is not made sterile, for example, methyl hydroxybenzoate, antioxidants, flavoring agents, volatile oils, buffering agents and surfactants.
  • Aerosols of solid particles comprising the active compound may likewise be produced with any solid particulate medicament aerosol generator.
  • Aerosol generators for administering solid particulate medicaments to a subject produce particles which are respirable, as explained above, and generate a volume of aerosol containing predetermined metered dose of medicament at a rate suitable for human administration.
  • One illustrative type of solid particulate aerosol generator is an insufflator.
  • Suitable formulations for administration by insufflation include finely comminuted powders which may be delivered by means of an insufflator or taken into the nasal cavity in the manner of a snuff.
  • the powder e.g., a metered dose thereof effective to carry out the treatments described herein
  • the powder is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened in situ and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump.
  • the powder employed in the insufflator consists either solely of the active ingredient or of powder blend comprising the active ingredient, a suitable powder diluent, such as lactose, and an optional surfactant.
  • the active ingredient typically comprises of 0.1 to 100% w/w of the formulation.
  • a second type of illustrative aerosol generator comprises a metered dose inhaler.
  • Metered dose inhalers are pressurized aerosol dispensers, typically containing a suspension or solution formulation of active ingredient in a liquified propellant. During use, these devices discharge the formulation through a valve adapted to deliver a metered volume, typically from 10 to 150 ⁇ l, to produce a fine particle spray containing the active ingredient.
  • Suitable propellants include certain chlorofluorocarbon compounds, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof.
  • the formulation may additionally contain one of more co-solvents, for example, ethanol, surfactants, such as oleic acid or sorbitan trioleate, antioxidants and suitable flavoring agents.
  • the aerosol may be produced by the aerosol generator at a rate of from about 10 to 150 liters per minute, more preferable from 30 to 150 liters per minute, and most preferably about 60 liters per minute. Aerosols containing greater amounts of medicament may be administered more rapidly.
  • the dosage of the active compounds disclosed herein will vary depending on the condition being treated and the state of the subject, but generally may be from about 0.01, 0.03, 0.05, 0.1 to 1, 5, 10 or 20 mg of the pharmaceutic agent, deposited on the airway surfaces.
  • the daily dose may be divided among one or multiple unit dose administrations.
  • the goal is to achieve a concentration of the pharmaceutic agents on lung airway surfaces of between 10 -9 - 10 4 M.
  • respirable or non-respirable particles preferably non-respirable particles
  • active compound which the subject inhales through the nose.
  • the respirable or non-respirable particles may be liquid or solid.
  • the quantity of active agent included may be an amount of sufficient to achieve dissolved concentrations of active agent on the airway surfaces of the subject of from about 10 -9 , 10 -8 , or 10 -7 to about 10 -3 , 10 -2 , 10 -1 moles/liter, and more preferably from about 10 -9 to about 10 -4 moles/liter.
  • the dosage of active compound will vary depending on the condition being treated and the state of the subject, but generally may be an amount sufficient to achieve dissolved concentrations of active compound on the nasal airway surfaces of the subject from about 10 -9 , 10 -8 , 10 -7 to about 10 -3 , 10 -2 , or 10 -1 moles/liter, and more preferably from about 10 -7 to about 10 -4 moles/liter.
  • the daily dose may be divided among one or several unit dose administrations.
  • the daily dose by weight may range from about 0.01, 0.03, 0.1, 0.5 or 1.0 to 10 or 20 milligrams of active agent particles for a human subject, depending upon the age and condition of the subject.
  • a currently preferred unit dose is about 0.5 milligrams of active agent given at a regimen of 2-10 administrations per day.
  • the dosage may be provided as a prepackaged unit by any suitable means (e.g., encapsulating a gelatin capsule).
  • the particulate active agent composition may contain both a free base of active agent and a pharmaceutically acceptable salt to provide both early release and sustained release of active agent for dissolution into the mucus secretions of the nose.
  • a composition serves to provide both early relief to the patient, and sustained relief over time. Sustained relief, by decreasing the number of daily administrations required, is expected to increase patient compliance with the course of active agent treatments.
  • compositions suitable for airway administration include formulations of solutions, emulsions, suspensions and extracts. See generally, J. Nairn, Solutions, Emulsions, Suspensions and Extracts, in Remington: The Science and Practice of Pharmacy, chap. 86 (19th ed. 1995 )
  • Pharmaceutical formulations suitable for nasal administration may be prepared as described in U.S. Patent Nos. 4,389,393 to Schor ; 5,707,644 to Illum ; 4,294,829 to Suzuki ; and 4,835,142 to Suzuki ,
  • Mists or aerosols of liquid particles comprising the active compound may be produced by any suitable means, such as by a simple nasal spray with the active agent in an aqueous pharmaceutically acceptable carrier, such as a sterile saline solution or sterile water. Administration may be with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer. See e.g. U.S. Patent No. 4,501,729 and 5,656,256 , Suitable formulations for use in a nasal droplet or spray bottle or in nebulizers consist of the active ingredient in a liquid carrier, the active ingredient comprising up to 40% w/w of the formulation, but preferably less than 20% w/w.
  • the carrier is water (and most preferably sterile, pyrogen-free water) or dilute aqueous alcoholic solution, preferably made in a 0.12% to 0.8% solution of sodium chloride.
  • Optional additives include preservatives if the formulation is not made sterile, for example, methyl hydroxybenzoate, antioxidants, flavoring agents, volatile oils, buffering agents, osmotically active agents (e.g. mannitol, xylitol, erythritol) and surfactants.
  • compositions containing respirable or non-respirable dry particles of micronized active agent may be prepared by grinding the dry active agent with a mortar and pestle, and then passing the micronized composition through a 400 mesh screen to break up or separate out large agglomerates.
  • the particulate composition may optionally contain a dispersant which serves to facilitate the formation of an aerosol.
  • a suitable dispersant is lactose, which may be blended with the active agent in any suitable ratio (e.g., a 1 to I ratio by weight).
  • the compounds of formula (I) may be synthesized according to procedures known in the art. A representative synthetic procedure is shown in the scheme below:
  • the compounds of the present invention involves the determination of lumenal drug inhibition of airway epithelial sodium currents measured under short circuit current (I SC ) using airway epithelial monolayers mounted in Ussing chambers.
  • I SC short circuit current
  • Cells obtained from freshly excised human, or dog airways are seeded onto porous 0.4 micrometer Transwell ® Permeable Supports (combing Inc. Acton, MA), cultured at air-liquid interface (ALI) conditions in hormonally defined media, and assayed for sodium transport activity (I SC ) while bathed in Krebs Bicarbonate Ringer (KBR) in Ussing chambers.
  • All test drug additions are to the lumenal bath with approximately half-log dose additions (from 1 x 10 -11 M to 6 x 10 -5 M), and the cumulative change in I SC (decreases) recorded.
  • All drugs are prepared in dimethyl sulfoxide as stock solutions at a concentration of approximately 1 x 10 -2 and stored at -20° C. Six preparations are typically run in parallel; one preparation per run incorporates 552-02 as a positive control.
  • a non-selective beta agonist blocker was applied to the lumenal bath (10 ⁇ M) to inhibit the beta agonist component of the designer multiple ligand (DML). All data from the voltage clamps are collected via a computer interface and analyzed off-line.
  • the compounds of the present invention involves the determination of lumenal drug addition to promote airway epithelial anion currents measured under short circuit current (I SC ) using airway epithelial monolayers mounted in Ussing chambers.
  • I SC short circuit current
  • Cells obtained from freshly excised human, dog, or sheep airways are seeded onto porous 0.4 micron Transwell ® Permeable Supports (Coming), cultured at air-liquid interface (ALI) conditions in hormonally defined media, and assayed for anion secretion (I SC ) while bathed in Krebs Bicarbonate Ringer (KBR) in Ussing chambers.
  • I SC short circuit current
  • All test drug additions are to the lumenal bath with approximately half-log dose additions (from 8 x 10 -10 M to 6.5 x 10 -5 M), and the cumulative change in I SC (excitation) recorded.
  • All drugs are prepared in dimethyl sulfoxide as stock solutions at a concentration from 1 x 10 -1 to 1 x 10 -2 M and stored at -20° C. Six preparations are typically run in parallel; one preparation per run incorporates either formoterol, salmeterol, or another well recognized beta agonists as a positive control depending on the anolog incorporated in the compound being tested.
  • Concentration-effect relationships for all compounds are considered and analyzed Using GraphPad Prism version 3.00 for Windows, GraphPad Software, San Diego California USA. EC 50 values, maximal effective concentrations, are calculated and compared to either formoterol or salbutamol as the positive control.
  • Airway epithelial cells have the capacity to metabolize drugs during the process of transepithelial absorption. Further, although less likely, it is possible that drugs can be metabolized on airway epithelial surfaces by specific ectoenzyme activities. Perhaps more likely as an ecto-surface event, compounds may be metabolized by the infected secretions that occupy the airway lumens of patients with lung disease, e.g. cystic fibrosis. Thus, a series of assays are performed to characterize any compound biotransformation (metabolism or conjugation) that results from the interaction of test compounds with human airway epithelia and/or human airway epithelial lumenal products.
  • test compounds in KBR as an "ASL" stimulant are applied to the apical surface of human airway epithelial cells grown in the Transwell ® Permeable Supports (Corning), insert system.
  • metabolism or conjugation generation of new species
  • HPLC high performance liquid chromatography
  • a test solution (1 mL KBR, containing 100 ⁇ M test compound) is placed on the epithelial lumenal surface.
  • Sequential 5 to 600 ⁇ l samples are obtained from the lumenal and serosal compartments respectively for HPLC analysis of (1) the mass of test compound permeating from the lumenal to serosal bath and (2) the potential formation of metabolites from the parent compound.
  • HPLC data From the HPLC data, the rate of and/or formation of novel metabolite compounds on the lumenal surface and the appearance of test compound and/or novel metabolite in the basolateral solution is quantitated based on internal standards.
  • the data relating the chromatographic mobility of potential novel metabolites with reference to the parent compound are also quantitated.
  • Typical studies of compound metabolism by CF sputum involve the addition of known masses of test compound to "neat" CF sputum and aliquots of CF sputum "supernatant" incubated at 37 °C, followed by sequential sampling of aliquots from each sputum type for characterization of compound stability/metabolism by HPLC analysis as described above. As above, analysis of compound disappearance, rates of formation of novel metabolities, and HPLC mobilities of novel metabolites are then performed.
  • GC-analysis was performed on a Shimadzu GC-17 equipped with a Heliflex Capillary Column (Alltech); Phase: AT-1, Length: 10 meters, ID: 0.53 mm, Film: 0.25 micrometers.
  • GC Parameters Injector at 320 °C, Detector at 320 °C, FID gas flow: H 2 at 40 ml/min., Air at 400 ml/min.
  • Carrier gas Split Ratio 16:1, N 2 flow at 15 ml/min., N 2 velocity at 18 cm/sec.
  • the temperature program is 70 °C for 0-3 min, 70-300 °C from 3-10 min, 300 °C from 10-15 min.
  • HPLC analysis was performed on a Gilson 322 Pump, detector UV/Vis-156 at 360 nm, equipped with a Microsorb MV C8 column, 100 A, 25 cm.
  • Phenyltrimethylammonium tribromide (1.46g, 3.90 mmol) was added to a solution of 1-(4-benzyloxy-3-nitrophenyl)ethanone ( 2 ) (1.04 g, 3.82 mmol) in anhydrous THF (15 mL) in three portions. The reaction mixture was stirred at rt for 12 h. Then an aqueous sodium bicarbonate solution (5%, 10 mL) and an aqueous sodium thiosulfate solution (10%, 5 mL) were added. The mixture was extracted with dichloromethane, and combined organics were concentrated by rotary evaporation.
  • the desired adduct 8 was isolated as a solid (0.14 g, 30%): 1 H NMR (500 MHz, CDCl 3 ) ⁇ 1.50 (m, 2H), 1.62 (m, 6H), 2.55 (m, 4H), 2.76 (m, 3H), 2.94 (dd, 1H), 3.18 (m, 2H), 3.96 (br, 2H), 4.82 (m, 2H), 5.06 (m, 4H), 6.92 (d, 1H), 7.05 (m, 4H), 7.13 (dd, 1H), 7.34 (m, 5H), 7.39 (m, 5H), 7.86 (br, 1H), 8.34 (dd, 1H); m / z (ESI) 624 [C 38 H 45 N 3 O 5 + H] + .
  • the isomeric adduct 9 (78 mg, 16%): 1 H NMR (500 MHz, CDCl 3 ) ⁇ 1.58 (m, 8H), 2.52 (m, 8H), 3.19 (m, 2H), 3.53 (dd, 1H), 3.69 (m, 2H), 4.78 (br, 1H), 5.08 (m, 4H), 6.95 (d, 1H), 7.05 (m, 5H), 7.32 (m, 5H), 7.40 (m, 5H), 7.82 (br, 1H), 8.35 (d, 1H); m / z (ESI) 624 [C 38 H 45 N 3 O 5 + H] + .
  • the catalyst was filtered through a Celite pad and the filtrate was concentrated by rotary evaporation and further dried under high vacuum to give the desired amine diacetic acid salt 13 as a white solid (0.10 mg, 98%): m / z (ESI) 579 [C 32 H 42 N 4 O 6 + H] + .
  • Benzyaldehyde (0.74 ml, 7.31 mmol) was added to a solution of 4-[4-(2-aminoethoxy) phenyl]butylcarbamic acid benzyl ester ( 15 ) (5.00 g ( ⁇ 50% purity by NMR), 7.30 mmol) dissolved in anhydrous dichloroethane (50 mL). The resulting solution was stirred at ambient temperature for 7 h. Sodium triacetoxyborohydride (4.10 g, 19.35 mmol) was added slowly and the reduction continued for 60 h. The reaction was quenched with aqueous sodium bicarbonate (50 mL) and then extracted with ethyl acetate (3 X 25 mL).
  • Benzylamine 16 (619 mg, 1.43 mmol) was added to a suspension of bromoalcohol 5 (500 mg, 1.43 mmol) and K 2 CO 3 (495 mg, 3.58 mmol) in methanol(10 mL) and tetrahydrofuran (5 mL). The suspension was stirred at ambient temperature for 15 h, then heated to 55 °C for 75 h. The solid was vacuum filtered and the filtrate was concentrated under vacuum.
  • ⁇ -Aminoalcohol 17 (500 mg, 0.71 mmol) was dissolved in ethanol (20 mL). Following the standard hydrogenation procedure, palladium dihydroxide (20% on carbon, 50% wet) was added. The reaction mixture was stirred for 15 h at ambient temperature under atmospheric H 2 pressure. The catalyst was removed by filtration through diatomaceous earth and the filtrate was concentrated to a yellow solid.
  • the diastereoisomer 29 (13 mg, 7%) was also isolated as a light yellow solid: 1 H NMR (300 MHz, CD 3 OD) ⁇ 1.26 (d, 3H), 1.48-1.90 (m, 8H), 2.50 (m, 4H), 2.82-3.08 (m, 3H), 3.50 (m, 2H), 4.60 (m, 1H), 6.82-6.82 (m, 2H), 7.10 (m, 5H), 8.00 (s, 1H), 8.28 (s, 1H); m / z (ESI) 414 [C 31 H 41 N 3 O 3 + H] + .
  • N -(5-acetyl-2-hydroxyphenyl)methanesulfonamide ( 31 ) (0.30 g, 1.32 mmol), sodium iodide (0.20 g, 1.32 mmol), potassium carbonate (0.91 g, 6.58 mmol), and benzyl bromide (0.39 mL, 3.28 mmol) in acetone (10 mL) was stirred under reflux for 66 h. After removal of solvent by rotary evaporation, the resulting residue was diluted with dichloromethane and insoluble inorganics were vacuum filtered.
  • Phenyltrimethylammonium tribromide (1.19 g, 3.16 mmol) was added to a solution of N -(5-acetyl-2-benzyloxyphenyl)- N -benzylmethanesulfonamide ( 32 ) (1.23g, 3.01 mmol) in anhydrous THF (15 mL) in three portions. The reaction mixture was stirred at rt for 16 h. An aqueous sodium bicarbonate solution (5%, 15 mL) was then added. The mixture was extracted with dichloromethane and combined organics were concentrated by rotary evaporation.
  • the desired epoxide 35 was obtained as a white solid (0.69 g, 90%) and used directly for next step without purification: 1 H NMR (500 MHz, CDCl 3 ) ⁇ 2.60 (m, 1H), 2.84 (s, 3H), 3.02 (dd, 1H), 3.66 (dd, 1H), 4.75 (br, 2H), 5.10 (s, 2H), 6.97 (d, 1H), 7.01 (d, 1H), 7.12 (dd, 1H), 7.22 (m, 5H), 7.41 (m, 5H).
  • the desired adduct 36 was isolated as a solid (0.41 g, 32%): 1 H NMR (500 MHz, CDCl 3 ) ⁇ 1.50 (m, 4H), 1.61 (m, 4H), 2.57 (m, 8H), 2.75 (br, 1H), 2.83 (s, 3H), 3.19 (m, 2H), 4.51 (dd, 1H), 4.77 (br, 3H), 5.07 (s, 2H), 5.08 (s, 2H), 6.96 (d, 1H), 6.98 (d, 1H), 7.06 (m, 4H), 7.19 (m, 5H), 7.27 (dd, 1H), 7.33 (m, 5H), 7.41 (m, 5H); m / z (ESI) 764 [C 45 H 53 N 3 O 6 S + H] + .
  • the isomeric adduct 37 (0.23 g, 18%): 1 H NMR (500 MHz, CDCl 3 ) ⁇ 1.40 (m, 2H), 1.58 (m, 6H), 2.15 (br, 2H), 2.29 (m, 2H), 2.52 (m, 2H), 2.58 (t, 2H), 2.86 (s, 3H), 3.19 (m, 2H), 3.32 (dd, 1H), 3.50 (m, 2H), 4.76 (br, 2H), 5.08 (s, 2H), 5.11 (s, 2H), 6.88 (d, 1H), 6.96 (d, 1H); 7.06 (m, 4H), 7.16 (m, 6H), 7.33 (m, 5H), 7.43(m, 5H); m / z (ESI) 764 [C 45 H 53 N 3 O 6 S + H] + .
  • the catalyst was removed by vacuum filtration through a Celite pad and the filtrate was concentrated by rotary evaporation and further dried under high vacuum to give the desired amine diacetic acid salt 41 as a white solid (0.30 g, 98%): m / z (ESI) 679 [C 32 H 42 N 4 O 6 + H] + .
  • Benzyl chloride (3.85 ml, 33.45 mmol) was added slowly to a 60 °C solution of salicylate 43 (5.00 g, 25.75 mmol), sodium iodide (386 mg, 2.57 mmol), and sodium bicarbonate (2.50 g, 29.75 mmol) in acetonitrile (50 mL).
  • the reaction was heated to reflux for 16 h.
  • the solvent was removed under vacuum.
  • the residue was taken up in ethyl acetate (50 mL), and washed sequentially with 0.5 N HCl (25 mL), water (25 mL), 5% ammonium chloride (25 mL) and then brine (25 mL).
  • Phenyltrimethyl ammonium tribromide (10.60 g, 28.20 mmol) was added in 7 portions to a stirring solution of acetophenone 44 (8.00 g, 28.10 mmol) in anhydrous tetrahydrofuran (50 mL). After 18 h, the reaction mixture was poured into water (250 mL) and stirred for 1 h. The formed precipitate was collected by vacuum filtration.
  • Diisobutylaluminum hydride (6.15 mL of a 1.0 M solution in hexanes, 6.15 mmol) was added slowly to a solution of phenyl ester 51 (702 mg, 1.23 mmol) in tetrahydrofuran (25 mL) stirring at 0 °C. The reaction was stirred for 15 min at 0 °C then warmed to ambient temperature. After 4.5 h, the reaction was cooled to 0 °C and quenched by the dropwise addition of methanol (10 mL). The reaction was concentrated to dryness and the residue was taken up in ethyl acetate. A saturated aqueous ammonium chloride solution was added into the solution.
  • Benzyl alcohol 52 (507 mg, 0.93 mmol) was dissolved in ethanol (20 mL). Following the standard hydrogenation protocol, the palladium catalyst (10% palladium on carbon, 50% wet) was added to the reaction. The hydrogenation was carried out for 15 h at ambient temperature under one H 2 pressure. Filtration of the catalyst through diatomaceous earth and concentration of the filtrate gave a yellow oil.
  • Phenyltrimethylammonium tribromide (28.60 g, 76.10 mmol) was added to a solution of N-(5-acetyl-2-benzyloxyphenyl)- N -benzylmethanesulfonamide ( 130 ) (29.60 g, 72.30 mmol) in anhydrous THF (150 mL) in four portions. The reaction mixture was stirred at ambient temperature for 14 h. The solids were removed by vacuum filtration and the filtrate concentrated by rotary evaporation.
  • Desired adduct 135 (0.35 g, 15% yield) was isolated as a white foam: 1 H NMR (500 MHz, CDCl 3 ) ⁇ 0.88-0.94 (m, 3H), 1.21-1.61 (m, 10H), 2.34-2.57 (m, 5H), 2.86 (m, 3H), 3.19 (m, 2H), 3.43-3.69(m, 2H), 4.77 (br s, 3H), 5.07 (m, 2H), 5.30 (s, 2H), 6.86 -7.43 (m, 22H); m / z (ESI) 778 [C 46 H 55 N 3 O 6 S + H] + .
  • ketone 140 (6.58 g , >99% yield) as a white solid: 1 H NMR (500 MHz, CDCl 3 ) ⁇ 1.50-1.56 (m, 2H), 1.60-1.66 (m, 2H), 1.85-1.90 (m, 2H), 2.11 (s, 3H), 2.42 (t, 2H), 2.56-2.60 (m, 4H), 3.19-3.23 (m, 2H), 4.70 (br s, 1H), 5.08 (s, 2H), 7.07 (s, 4H), 7.29-7.36 (m, 5H).
  • Diisopropylethylamine (0.45 mL, 2.58 mmol) was added to a mixture of amino alcohol 142 (0.63 g, 1.69 mmol) and 1-(3,5-diamino-6-chloropyrazine-2-carbonyl)-2-methylisothiourea hydriodide (0.66 g, 2.58 mmol) in absolute ethanol (10 mL). The mixture was stirred at 75 °C (oil bath) for 4.5 h. After this time the mixture was cooled to rt and the solvent was removed by rotary evaporation.
  • Diisopropylethylamine (0.08 mL, 0.46 mmol) was added to a mixture of amino alcohol 146a (0.11 g, 0.28 mmol) and 1-(3,5-diamino-6-chloropyrazine-2-carbonyl)-2-methylisothiourea hydriodide ( 5 ) (0.11 g, 0.28 mmol) in absolute ethanol (3 mL).
  • the mixture was stirred at 75 °C (oil bath) for 5.5 h. After this time the mixture was cooled to rt and the solvent was removed by rotary evaporation.
  • MCC mucociliary clearance
  • Aerosols of sulfur colloid radiolabled with technetium were generated by a Raindrop Nebulizer (Nellcor Puritan Bennett, Pleasanton, CA) which produces a median aerodynamic droplet diameter of 3.6 ⁇ m.
  • the nebulizer was connected to a dosimeter system consisting of a solenoid valve and a source of compressed air (20 psi). The output of the nebulizer was directed into a T piece, with one end attached to a respirator (Harvard apparatus, South Natick, MA). The system was activated for 1 second at the onset of the respirator's inspiratory cycle.
  • the tidal volume was set at 300 mL, with an inspiratory-to-expiratory ratio of 1:1, and a rate of 20 breaths/min, to maximize central airway deposition.
  • the sheep breathed the 99mTc-SC aerosol for up to 5 min.
  • a gamma camera was used to measure the clearance of 99mTc-SC from the airways. The camera was positioned above the animal's back with the sheep in its natural upright position in the harness. The field of the image was perpendicular to the animal's spinal cord. External radiolabled markers were placed on the sheep to facilitate proper alignment of the gamma camera. A region of interest was traced over the image corresponding to the right lung of the sheep and counts were recorded.
  • the counts were corrected for decay and expressed as a percentage of radioactivity present in the baseline image.
  • the left lung was excluded from the analysis because the outline of the lung was superimposed over the stomach and counts could be affected by swallowed 99mTc-SC - labeled mucus.
  • All deposition images were stored on a computer interfaced to the gamma camera.
  • the protocol included a baseline deposition image obtained immediately post radio-aerosol administration. After acquisition of baseline images, either 4 mL of H 2 O (vehicle), formoterol (3 mM), or novel chemical entity (3 mM) were aerosolized using the Pari LC JetPlus nebulizer to free-breathing sheep using two separate protocols.
  • Protocol 1 acquired data immediately after dosing (time 0 to 1 hour), and indicated the immediate physiological response 'short-term efficacy' protocol 2, acquired data 4 hours post dosing indicated compound durability and ⁇ long-term efficacy'.
  • the nebulizer had a flow rate of 8 L/min and the time to deliver the solution was 10 - 12 min.
  • the animal was immediately extubated to prevent false elevations in counts due to aspiration of excess 99mTc-SC -labeled mucus from the ETT.
  • Aerosols of 99m Tc-Human serum albumin (3.1 mg/ml; containing approximately 20 mCi) were generated using a Raindrop Nebulizer which produces a droplet with a median aerodynamic diameter of 3.6 ⁇ m.
  • the nebulizer was connected to a dosimetry system consisting of a solenoid valve and a source of compressed air (20 psi).
  • the output of the nebulizer was directed into a plastic T connector; one end of which was connected to the endotracheal tube, the other was connected to a piston respirator. The system was activated for one second at the onset of the respirator's inspiratory cycle.
  • the respirator was set at a tidal volume of 500 mL, an inspiratory to expiratory ratio of 1:1, and at a rate of 20 breaths per minute to maximize the central airway deposition.
  • the sheep breathed the radio-labeled aerosol for 5 minutes.
  • a region of interest was traced over the image corresponding to the right lung of the sheep and the counts were recorded. The counts were corrected for decay and expressed as percentage of radioactivity present in the initial baseline image.
  • the left lung was excluded from the analysis because its outlines are superimposed over the stomach and counts can be swallowed and enter the stomach as radio-labeled mucus.
  • Treatment Protocol (Assessment of activity at t-zero): A baseline deposition image was obtained immediately after radio-aerosol administration. At time zero, after acquisition of the baseline image, vehicle control (distilled water), positive control (amiloride), or experimental compounds were aerosolized from a 4 ml volume using a Pari LC JetPlus nebulizer to free-breathing animals. The nebulizer was driven by compressed air with a flow of 8 liters per minute. The time to deliver the solution was 10 to 12 minutes. Animals were extubated immediately following delivery of the total dose in order to prevent false elevations in counts caused by aspiration of excess radio-tracer from the ETT. Serial images of the lung were obtained at 15-minute intervals during the first 2 hours after dosing and hourly for the next 6 hours after dosing for a total observation period of 8 hours. A washout period of at least 7 days separated dosing sessions with different experimental agents.
  • Treatment Protocol (Assessment of Activity at t-4hours): The following variation of the standard protocol was used to assess the durability of response following a single exposure to vehicle control (distilled water), positive control compounds (amiloride or benzamil), or investigational agents. At time zero, vehicle control (distilled water), positive control (amiloride), or investigational compounds were aerosolized from a 4 ml volume using a Pari LC JetPlus nebulizer to free-breathing animals. The nebulizer was driven by compressed air with a flow of 8 liters per minute. The time to deliver the solution was 10 to 12 minutes. Animals were restrained in an upright position in a specialized body harness for 4 hours.
  • mice received a single dose of aerosolized 99m Tc-Human serum albumin (3.1 mg/ml; containing approximately 20 mCi) from a Raindrop Nebulizer. Animals were extubated immediately following delivery of the total dose of radio-tracer. A baseline deposition image was obtained immediately after radio-aerosol administration. Serial images of the lung were obtained at 15-minute intervals during the first 2 hours after administration of the radio-tracer (representing hours 4 through 6 after drug administration) and hourly for the next 2 hours after dosing for a total observation period of 4 hours. A washout period of at least 7 days separated dosing sessions with different experimental agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07784388A 2006-06-09 2007-06-11 Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity Not-in-force EP2035004B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200731054T SI2035004T1 (sl) 2006-06-09 2007-06-11 S fenilom substituirani pirazinoilgvanidinski blokatorji natrijevih kanalov, ki imajo beta-agonistiäśno aktivnost
PL07784388T PL2035004T3 (pl) 2006-06-09 2007-06-11 Podstawione fenylem pirazynoiloguanidynowe blokery kanału sodowego o aktywności beta-agonistycznej
CY20121101054T CY1113369T1 (el) 2006-06-09 2012-11-06 Αναστολεις διαυλου νατριου φαινυλυποκατεστημενης πυραζινοϋλγουανιδινης που εχουν δραστικοτητα βητα αγωνιστη

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81207706P 2006-06-09 2006-06-09
PCT/US2007/070861 WO2007146869A1 (en) 2006-06-09 2007-06-11 Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity

Publications (3)

Publication Number Publication Date
EP2035004A1 EP2035004A1 (en) 2009-03-18
EP2035004A4 EP2035004A4 (en) 2010-06-30
EP2035004B1 true EP2035004B1 (en) 2012-08-08

Family

ID=38832114

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07784388A Not-in-force EP2035004B1 (en) 2006-06-09 2007-06-11 Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity

Country Status (12)

Country Link
US (1) US8163758B2 (pl)
EP (1) EP2035004B1 (pl)
JP (1) JP5254961B2 (pl)
AU (1) AU2007257781B2 (pl)
CA (1) CA2654244A1 (pl)
DK (1) DK2035004T3 (pl)
ES (1) ES2392999T3 (pl)
NO (1) NO20085128L (pl)
PL (1) PL2035004T3 (pl)
PT (1) PT2035004E (pl)
SI (1) SI2035004T1 (pl)
WO (1) WO2007146869A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
ES2432529T3 (es) 2003-08-18 2013-12-04 Parion Sciences, Inc. Bloqueadores del canal de sodio de pirazinoilguanidina rematada
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
KR100901664B1 (ko) 2007-08-06 2009-06-09 주식회사 오스코텍 β-아미노알콜 유도체, 이의 제조방법 및 이를유효성분으로 함유하는 ＴＮＦ-α 매개성 질환의 예방 및치료용 약학적 조성물
DE102007040615A1 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
DE102007052380A1 (de) * 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
EP2257296B1 (en) 2008-02-26 2014-05-07 Parion Sciences, Inc. Poly aromatic sodium channel blockers
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2012032546A2 (en) * 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
WO2012170677A1 (en) 2011-06-07 2012-12-13 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
DK2723176T3 (en) * 2011-06-27 2017-07-31 Parion Sciences Inc CHEMICAL AND METABOLIC STABLE DIPEPTIDE WITH POTENT SODIUM CHANNEL BLOCK ACTIVITY
AR086745A1 (es) * 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
MY171122A (en) 2012-05-29 2019-09-26 Parion Sciences Inc Dendrimer like amino amides processing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
GEP20186903B (en) 2012-12-17 2018-10-25 Saiensis Ink Perion Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
MX368243B (es) 2013-08-23 2019-09-25 Parion Sciences Inc Agentes mucolíticos de ditiol.
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
CN107614480B (zh) 2015-01-30 2020-09-15 帕里昂科学公司 新型单硫醇粘液溶解剂
CA2984424A1 (en) 2015-04-30 2016-11-03 Parion Sciences, Inc. Novel prodrugs of dithiol mucolytic agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR034000A0 (en) * 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
EP1670475A4 (en) * 2003-08-18 2009-04-15 Parion Sciences Inc ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
ES2432529T3 (es) * 2003-08-18 2013-12-04 Parion Sciences, Inc. Bloqueadores del canal de sodio de pirazinoilguanidina rematada
JP2007502829A (ja) * 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
US7745442B2 (en) * 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
CA2575680A1 (en) * 2004-08-18 2006-03-02 Michael R. Johnson Cyclic amide & ester pyrazinoylguanidine sodium channel blockers
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) * 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
WO2008031028A2 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
WO2008124496A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
WO2008124491A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators

Also Published As

Publication number Publication date
EP2035004A1 (en) 2009-03-18
EP2035004A4 (en) 2010-06-30
PT2035004E (pt) 2012-11-21
AU2007257781B2 (en) 2012-11-22
US20110008268A1 (en) 2011-01-13
PL2035004T3 (pl) 2013-01-31
WO2007146869A1 (en) 2007-12-21
NO20085128L (no) 2009-02-18
CA2654244A1 (en) 2007-12-21
SI2035004T1 (sl) 2012-12-31
JP2009539882A (ja) 2009-11-19
JP5254961B2 (ja) 2013-08-07
US8163758B2 (en) 2012-04-24
DK2035004T3 (en) 2013-01-02
ES2392999T3 (es) 2012-12-17
AU2007257781A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
EP2035004B1 (en) Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
US10167266B2 (en) Sodium channel blockers
US8324218B2 (en) Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
US7368450B2 (en) Sodium channel blockers
US7317013B2 (en) Cyclic pyrazinoylguanidine sodium channel blockers
US6903105B2 (en) Sodium channel blockers
US20080200476A1 (en) Alaphatic pyrazinoylguanidine sodium channel blockers
EP1670475A2 (en) Alaphatic pyrazinoylguanidine sodium channel blockers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20100602

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/497 20060101AFI20100527BHEP

Ipc: A61P 17/04 20060101ALI20100527BHEP

Ipc: A61P 31/00 20060101ALI20100527BHEP

Ipc: A61K 31/4965 20060101ALI20100527BHEP

Ipc: A61P 11/00 20060101ALI20100527BHEP

Ipc: A61P 13/00 20060101ALI20100527BHEP

Ipc: A61P 27/04 20060101ALI20100527BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110624

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 241/32 20060101ALI20111222BHEP

Ipc: A61P 27/04 20060101ALI20111222BHEP

Ipc: A61P 17/04 20060101ALI20111222BHEP

Ipc: A61P 13/00 20060101ALI20111222BHEP

Ipc: A61P 11/00 20060101ALI20111222BHEP

Ipc: A61P 31/00 20060101ALI20111222BHEP

Ipc: A61K 31/4965 20060101ALI20111222BHEP

Ipc: A61K 31/497 20060101AFI20111222BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 569367

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120815

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007024602

Country of ref document: DE

Effective date: 20120927

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20121108

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2392999

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20121217

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E007305

Country of ref document: EE

Effective date: 20121107

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120402543

Country of ref document: GR

Effective date: 20130122

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 13855

Country of ref document: SK

26N No opposition filed

Effective date: 20130510

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E015959

Country of ref document: HU

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20130520

Year of fee payment: 7

Ref country code: IE

Payment date: 20130625

Year of fee payment: 7

Ref country code: CZ

Payment date: 20130529

Year of fee payment: 7

Ref country code: MC

Payment date: 20130527

Year of fee payment: 7

Ref country code: SE

Payment date: 20130627

Year of fee payment: 7

Ref country code: IS

Payment date: 20130521

Year of fee payment: 7

Ref country code: DK

Payment date: 20130625

Year of fee payment: 7

Ref country code: CH

Payment date: 20130627

Year of fee payment: 7

Ref country code: SK

Payment date: 20130520

Year of fee payment: 7

Ref country code: EE

Payment date: 20130522

Year of fee payment: 7

Ref country code: DE

Payment date: 20130627

Year of fee payment: 7

Ref country code: GB

Payment date: 20130627

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20130522

Year of fee payment: 7

Ref country code: TR

Payment date: 20130524

Year of fee payment: 7

Ref country code: PL

Payment date: 20130523

Year of fee payment: 7

Ref country code: HU

Payment date: 20130529

Year of fee payment: 7

Ref country code: LV

Payment date: 20130521

Year of fee payment: 7

Ref country code: FI

Payment date: 20130627

Year of fee payment: 7

Ref country code: FR

Payment date: 20130702

Year of fee payment: 7

Ref country code: GR

Payment date: 20130627

Year of fee payment: 7

Ref country code: SI

Payment date: 20130531

Year of fee payment: 7

Ref country code: RO

Payment date: 20130603

Year of fee payment: 7

Ref country code: LU

Payment date: 20130702

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007024602

Country of ref document: DE

Effective date: 20130510

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20130627

Year of fee payment: 7

Ref country code: BG

Payment date: 20130627

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20130626

Year of fee payment: 7

Ref country code: CY

Payment date: 20130527

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20130621

Year of fee payment: 7

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20141211

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007024602

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20140630

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20150101

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20140611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141211

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140612

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 569367

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140611

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E007305

Country of ref document: EE

Effective date: 20140630

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141231

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20130626

Year of fee payment: 7

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 13855

Country of ref document: SK

Effective date: 20140611

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20120402543

Country of ref document: GR

Effective date: 20150105

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007024602

Country of ref document: DE

Effective date: 20150101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150101

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20150213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140612

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150105

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140612

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140611